“3-Hydroxybutyric acid CAS 625-71-8” has been added to your cart. View cart

Favipiravir CAS 259793-96-9

81 sold in last 3 hours

Hurry! Over 50 people have this in their carts

Chemical Name: Favipiravir
CAS No.: 259793-96-9
Molecular Fomula: C5H4FN3O2
Molecular weight: 157.1
Appearance: Off white solid
Assay: 99 % min

Estimated Delivery: Sat, Aug 30 – Wed, Sep 03

... people are viewing this right now

Guaranteed Safe Checkout

Favipiravir (CAS 259793-96-9) User Guide & Procurement Resource

1. Product Specifications & Comparative Analysis
2. Clinical Applications & Therapeutic Uses
3. Operational Protocols & Administration Guidelines
4. Global Implementation Case Studies
5. Verified Client Success Stories
6. Supplier Inquiry & Technical Support

1. Product Specifications & Comparative Analysis

Parameter	Favipiravir	Analog Antivirals
CAS Number	259793-96-9	N/A
Molecular Formula	C₅H₄FN₃O₂	Varies
Purity Grade	≥98% (Pharmaceutical)	90-99%
Therapeutic Class	RNA Polymerase Inhibitor	Neuraminidase Inhibitors

2. Clinical Applications & Therapeutic Uses

Primary Indications:

Influenza A/B virus infection (FDA-approved in Japan)
Emergency Use Authorization for COVID-19 (Selected Countries)
Experimental treatment for Ebola & Lassa fever

Mechanism of Action: Selective inhibition of viral RNA-dependent RNA polymerase with minimal host cell toxicity.

3. Operational Protocols & Administration Guidelines

Dosage Regimen:

Patient Group	Loading Dose	Maintenance Dose
Adults (≥20kg)	1,600mg bid (Day 1)	600mg bid (Days 2-5)
Renal Impairment	Dose adjustment not required

4. Global Implementation Case Studies

Case 1: Pandemic Response (Japan 2020)
– 78% reduction in viral load within 72 hours
– Hospitalization duration decreased by 4.2 days vs standard care

Case 2: COVID-19 Outbreak Control (India 2021)
– 2,500 patients treated under emergency protocol
– 89% showed clinical improvement within 5-day course

5. Verified Client Success Stories

Pharmaceutical Manufacturer A (Germany):
– Annual procurement: 850kg
– Application: Oral tablet formulation development
– Outcome: Achieved 98.7% bioavailability in Phase III trials

National Health Organization B (Southeast Asia):
– 12-month emergency stockpile: 2.3 metric tons
– Implementation: Reduced ICU admissions by 62% during peak epidemic

6. Supplier Inquiry & Technical Support

Contact our antiviral specialists for:
– Batch-specific COA documentation
– Regulatory compliance assistance
– Custom synthesis solutions
Email: info@vivalr.com
Tel: (86) 15866781826

Request Immediate Quotation:
Specify required quantity, purity grade, and delivery timeline for prompt response.

0.00

0 reviews